We are live on ! Find out more
VKTX icon

Viking Therapeutics

138 hedge funds and large institutions have $227M invested in Viking Therapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 52 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

320% more call options, than puts

Call options by funds: $7.14M | Put options by funds: $1.7M

4% less funds holding

Funds holding: 144138 (-6)

7.54% less ownership

Funds ownership: 56.03%48.49% (-7.5%)

13% less capital invested

Capital invested by funds: $260M → $227M (-$33.3M)

25% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 20

25% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 52

Holders
138
Holders Change
-6
Holders Change %
-4.17%
% of All Funds
2.4%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
39
Reduced
52
Closed
20
Calls
$7.14M
Puts
$1.7M
Net Calls
+$5.44M
Net Calls Change
-$935K
Name Holding Trade Value Shares
Change
Change in
Stake
ACH
1
ArrowMark Colorado Holdings
Colorado
$45.9M +$129K +21,700 +0.3%
BlackRock
2
BlackRock
New York
$31.4M -$517K -87,060 -2%
State Street
3
State Street
Massachusetts
$29.9M -$10.7M -1,798,484 -27%
Vanguard Group
4
Vanguard Group
Pennsylvania
$19.7M +$206K +34,619 +1%
PWAM
5
Park West Asset Management
California
$9.99M +$419K +70,600 +4%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$6.95M +$568K +95,701 +9%
Fiera Capital (Canada)
7
Fiera Capital (Canada)
Quebec, Canada
$6.5M -$178K -30,020 -3%
Northern Trust
8
Northern Trust
Illinois
$5.99M -$6.19K -1,043 -0.1%
Two Sigma Advisers
9
Two Sigma Advisers
New York
$5.9M -$249K -42,000 -4%
Two Sigma Investments
10
Two Sigma Investments
New York
$4.96M -$1.75M -294,887 -26%
SCM
11
Sio Capital Management
New York
$3.71M +$297K +50,000 +9%
IC
12
Ikarian Capital
Texas
$3.14M -$1.19M -200,000 -28%
Morgan Stanley
13
Morgan Stanley
New York
$2.69M +$1.94M +326,954 +269%
DCM
14
DAFNA Capital Management
California
$2.68M
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$2.01M +$139K +23,474 +8%
Macquarie Group
16
Macquarie Group
Australia
$1.99M
PPA
17
Parametric Portfolio Associates
Washington
$1.82M +$266K +44,730 +17%
New York State Common Retirement Fund
18
New York State Common Retirement Fund
New York
$1.81M +$3.24K +545 +0.2%
Goldman Sachs
19
Goldman Sachs
New York
$1.75M +$1.44M +242,938 +495%
Citigroup
20
Citigroup
New York
$1.73M -$851K -143,347 -33%
Deutsche Bank
21
Deutsche Bank
Germany
$1.7M -$8.92K -1,502 -0.5%
N
22
Nuveen
North Carolina
$1.7M -$78.4K -13,210 -4%
Bank of America
23
Bank of America
North Carolina
$1.66M -$661K -111,343 -29%
RJA
24
Raymond James & Associates
Florida
$1.55M -$845K -142,309 -35%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$1.53M +$294K +49,524 +24%

VKTX Hedge Fund Activity: Q2 2021 in Review

138 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2021, worth a combined $227M — down 13% from $260M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of VKTX and 15 opened new positions — a net loss of 5 holders — while 52 trimmed existing stakes and 39 added.

The largest buyer was Morgan Stanley, adding an estimated $1.94M. The largest seller was State Street, cutting an estimated $10.7M.

  • 138 institutional investors held Viking Therapeutics (VKTX) as of Q2 2021, down from 144 in Q1 2021.
  • Funds reported $227M of Viking Therapeutics stock for Q2 2021, down 13% quarter-over-quarter.
  • 15 funds opened new Viking Therapeutics positions in Q2 2021 and 20 closed out, a net change of -5 holders.
  • The largest Viking Therapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $1.94M added.
  • The largest Viking Therapeutics seller in Q2 2021 was State Street, an estimated $10.7M sold.

Based on aggregated 13F filings for Q2 2021.